These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8842923)

  • 41. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
    Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of different beta-lactams in combination with beta-lactamase inhibitors in the presence or absence of tobramycin against some enterobacteriaceae producing extended-spectrum beta-lactamases.
    Ferrara A; Dos Santos C; Cimbro M
    Chemotherapy; 1998; 44(5):313-7. PubMed ID: 9732145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aminoglycosides: current role in antimicrobial therapy.
    Cunha BA
    Pharmacotherapy; 1988; 8(6):334-50. PubMed ID: 3146747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Properties of a broad spectrum beta-lactamase isolated from Flavobacterium meningosepticum GN14059.
    Fujii T; Sato K; Yokota E; Maejima T; Inoue M; Mitsuhashi S
    J Antibiot (Tokyo); 1988 Jan; 41(1):81-5. PubMed ID: 3257961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical role of beta-lactam/beta-lactamase inhibitor combinations.
    Lee N; Yuen KY; Kumana CR
    Drugs; 2003; 63(14):1511-24. PubMed ID: 12834367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stigmasterol: An adjuvant for beta lactam antibiotics against beta-lactamase positive clinical isolates.
    Yenn TW; Arslan Khan M; Amiera Syuhada N; Chean Ring L; Ibrahim D; Tan WN
    Steroids; 2017 Dec; 128():68-71. PubMed ID: 29104098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bactericidal effect of beta-lactams and amikacin alone or in association against Klebsiella pneumoniae producing extended spectrum beta-lactamase.
    Roussel-Delvallez M; Sirot D; Berrouane Y; Goffart M; Gourde B; Wallet F; Courcol RJ
    J Antimicrob Chemother; 1995 Jul; 36(1):241-6. PubMed ID: 8537274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
    Lerner SA; Quinn JP
    Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.
    Chandrasekar PH; Sluchak JA
    Infection; 1991; 19(1):49-53. PubMed ID: 2013510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Beta-lactamases with a wide substrate spectrum in gram negative strictly anaerobic rods].
    Rokosz A; Sawicka-Grzelak A; Kot K; Pituch H; Meisel-Mikołajczyk F; Luczak M
    Med Dosw Mikrobiol; 2000; 52(2):129-37. PubMed ID: 11107787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.
    Hart SM; Bailey EM
    Ann Pharmacother; 1996 Oct; 30(10):1130-40. PubMed ID: 8893121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes].
    Watanabe K; Kato N; Tanaka-Bandoh K; Tanaka Y; Kato H; Ueno K
    Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New antibiotics: carbapenems, monobactams and quinolones.
    Amin NM
    Am Fam Physician; 1988 Oct; 38(4):125-34. PubMed ID: 3051970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
    Harris PN; Ferguson JK
    Int J Antimicrob Agents; 2012 Oct; 40(4):297-305. PubMed ID: 22824371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.